Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Levi Strauss & Co. — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.6 (market cap $30.93B), while Levi Strauss & Co. trades at $19.6 (market cap $7.50B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 4.1× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (3.27%). Which is the better fit depends on your goals.
| GEHC | LEVI | |
|---|---|---|
Market Cap | $30.93B | $7.50B |
Volume | 5,033,451 | 4,326,665 |
Sector | Health | Consumer Cyclical |
52-Week High | $88.16 | $25.53 |
52-Week Low | $59.48 | $17.92 |
Enterprise Value | $39.39B | $9.06B |
Dividend Yield | 0.23% | 3.27% |
Typical Hold Time | — | 71 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Levi Strauss (LEVI) trades at $19.48, up 1.25% with strong fundamentals including a P/E of 12.82 and robust profitability metrics. The stock shows bearish technical signals but has consistently beaten earnings expectations for four consecutive quarters. Recent news highlights the company's successful '90s fashion revival and appointment of a new CFO, while analyst consensus remains strongly bullish with a $29 price target representing 49% upside potential.
LEVI presents a compelling value opportunity with attractive valuation multiples and strong earnings momentum, though technical indicators suggest near-term weakness. Key risks include execution challenges in DTC expansion and competitive pressures in the apparel sector. The 49% upside to analyst targets and consistent earnings beats support a positive long-term outlook despite current technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
